Recent Publications

Recent Publications

2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

2019

Dec 05, 2019
Mizutani, A. and Seimiya, H.
Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
Biochem. Biophys. Res. Commun., in press (2019)
Nov 29, 2019
Luangxay, T., Osako, T., Yonekura, R., Sugiura, Y., Kikuchi, M., Gomi, N., Ueno, T., Ohno, S., Machinami, R., Takeuchi, K. and Akiyama, F.
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature.
Pathobiology Reseach and Practice, in press (2019)
Nov 21, 2019
Goto, O., Sugiyama, Y., Takazawa, Y., Kato, K., Tanaka, N., Omatsu, K., Takeshima, N., Nomura, H., Hasegawa, K., Fujiwara, K., Taki, M., Matsumura, N., Noda, T. and Mori, S.
Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.
Nat. Commun., 10, 4965 (2019)
Nov 20, 2019
Sugiyama, Y., Gotoh, O., Fukui, N., Tanaka, N., Hasumi, K., Takazawa, Y., Noda, T. and Mori, S.
Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma.
Am. J. Pathol., in press (2019)
Oct 15, 2019
Mashima, T., Iwasaki, R., Kawata, N., Kawakami, R., Kumagai, K., Migita, T., Sano, T., Yamaguchi, K. and Seimiya, H.
In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Br. J. Cancer., in press (2019)
Sep 30, 2019
Udagawa, C., Horinouchi, H., Shiraishi, K., Kohno, T., Okusaka, T., Ueno, H., Tamura, K., Ohe, Y. and Zembutsu, H.
Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease.
PLoS One, in press (2019)
Sep 30, 2019
Hara-Nakano, M., Udagawa, C., Shimo, A., Kojima, Y., Yoshie, R., Zaha, H., Abe, N., Tokiwa, M., Uensoko, M., Tamura, K., Shimoi , T., Yoshida, M., Yoshida, T., Sakamoto, H., Kato, K., Mushiroda, T., Tsugawa, K. and Zembutsu, H.
A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population.
Biol. Pharm. Bull., in press (2019)
Aug 09, 2019
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., Shimizu, Y., Seto, Y., Oh-hara, T., Koike, S., Nakao, N., Hanazawa, H., Watanabe, K., Yoda, S., Yanagitani, N., Hata, A. N., Shaw, A. T., Nishio, M., Fujita, N. and Isoyama, T.
The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Nat. Commun., in press (2019)

ニュースリリース文章はこちら
Jul 23, 2019
Suzuki, Y., Kobayashi, K., Wakisaka, Y., Deng, D., Tanaka, S., Huang, C. J., Lei, C., Liu, H., Fujiwaki, Y., lee, S., isozaki, A., Kasai, Y., hayakawa, T., Sakuma, S., Arai, F., Koizumi, K., Tezuka, H., Inaba, M., hiraki, K., Ito, T., Hase, M., Matsusaka, S., Shiba, K., Suga, K., Nishikawa, M., Jona, M., Yatomi, Y., Yaxiaer, Y., Tanaka, Y., Sugimura, T., Nitta, N., Goda, K. and Yasuyuki, O.
Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering.
Proc. Natl. Acad. Sci. U. S. A., in press (2019)
Apr 04, 2019
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and Katayama, R.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
EBioMedicine, 41, 105-119 (2019)
Apr 04, 2019
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., Takeuchi, K., Kawamoto, H., Fujita, N. and Katayama, R.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
J. Exp. Med., 216, 982-1000 (2019)
Mar 07, 2019
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., nakayama, I., Osumi, H., Ota, Y., Takahari, D., Chin, K., Seimiya, H. and yamaguchi, K.
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Invest. New Drugs., in press (2019)
Mar 04, 2019
Matsumura, S., Minamisawa, T., Suga, K., Kishita, H., Akagi, T., Ichiki, T., Ichikawa, Y. and Shiba, K.
Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
J. Extracell. Vesicles, 8, (2019)
Feb 25, 2019
Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H.
Clinical utility of circulating tumor DNA for colorectal cancer.
Cancer Sci., in press (2019)
Jan 31, 2019
Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T. and Zembutsu, H.
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Cancer Med., 8, 408-417 (2019)

Return to Top of Page